Collectively, the data presented here demonstrate that BRY805 can activate natural killer (NK) cells, thereby enhancing NK cell-mediated cytotoxicity against HLA-E+ tumor cells, synergizing with PD-L1 inhibitors, cetuximab or trastuzumab, and inhibiting tumor growth in vivo. This evidence concerns the gene CD274 and neoplasm.